Alpha Or Leukocyte Patents (Class 424/85.7)
-
Publication number: 20150147295Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.Type: ApplicationFiled: November 13, 2014Publication date: May 28, 2015Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
-
Publication number: 20150139950Abstract: The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection.Type: ApplicationFiled: November 13, 2014Publication date: May 21, 2015Applicant: Novartis AGInventor: Claudio Avila
-
Publication number: 20150139951Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.Type: ApplicationFiled: February 2, 2015Publication date: May 21, 2015Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
-
Publication number: 20150139949Abstract: The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.Type: ApplicationFiled: May 19, 2014Publication date: May 21, 2015Inventors: Emre KOYUNCU, Thomas E. SHENK, Joshua RABINOWITZ
-
Publication number: 20150139947Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: October 31, 2014Publication date: May 21, 2015Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
-
Patent number: 9034310Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.Type: GrantFiled: February 20, 2003Date of Patent: May 19, 2015Inventor: Stephen B. Cantrell
-
Publication number: 20150132258Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: ApplicationFiled: November 14, 2014Publication date: May 14, 2015Inventor: George D. Hartman
-
Publication number: 20150132261Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.Type: ApplicationFiled: April 30, 2013Publication date: May 14, 2015Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
-
Publication number: 20150132260Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: ApplicationFiled: April 19, 2013Publication date: May 14, 2015Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Publication number: 20150132217Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.Type: ApplicationFiled: January 20, 2015Publication date: May 14, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
-
Publication number: 20150126402Abstract: A method for quantifying metallothionein protein isomers is described herein. Such metallothionein isomer protein quantification is useful for detecting and monitoring disease. As illustrated herein, protein quantification is a more accurate measure of metallothionein induction than is mRNA quantification.Type: ApplicationFiled: May 17, 2013Publication date: May 7, 2015Inventors: John B. Shabb, Aaron Mehus, Wallace Muhonen, Donald A. Sens, Scott Garrett
-
Publication number: 20150125423Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Inventors: Jennifer Mitcham, Matthew Moyle
-
Publication number: 20150125422Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
-
Publication number: 20150118186Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: January 5, 2015Publication date: April 30, 2015Inventors: Jordi BACH TAÑA, Lluis Miquel PAGES SANTACANA, Joan TALTAVULL MOLL, Paul Robert EASTWOOD, Jacob GONZALEZ RODRIGUES, Victor GIULIO MATASSA
-
Publication number: 20150118187Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon.Type: ApplicationFiled: October 22, 2014Publication date: April 30, 2015Applicant: MEDGENICS MEDICAL ISRAEL LTD.Inventors: Nir Shapir, Reem Miari, Baruch S. Stern, Shany Blum, Avi Rimler
-
Publication number: 20150110736Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
-
Publication number: 20150110742Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.Type: ApplicationFiled: May 1, 2013Publication date: April 23, 2015Applicant: Yale UniversityInventors: David Spiegel, Kelly Fitzgerald
-
Patent number: 9011833Abstract: The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.Type: GrantFiled: October 7, 2011Date of Patent: April 21, 2015Assignee: Novartis AGInventors: Sudhakar Devidasrao Garad, Anasuya Ashok Ghosh, Jay Parthiban Lakshman, Lipa Shah, Radha Vippagunta
-
Publication number: 20150104416Abstract: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventor: Dennis Brown
-
Publication number: 20150104415Abstract: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.Type: ApplicationFiled: April 11, 2012Publication date: April 16, 2015Applicants: DEBIOPHARM INTERNATIONAL SA, NOVARTIS AGInventors: Claudio Avila, Rafael Crabbe
-
Patent number: 9005598Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.Type: GrantFiled: March 4, 2010Date of Patent: April 14, 2015Assignee: Polytherics LimitedInventors: Antony Robert Godwin, Stephen James Brocchini
-
Publication number: 20150098926Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis.Type: ApplicationFiled: September 12, 2014Publication date: April 9, 2015Inventors: Melanie Ott, Eva Herker, Robert V. Farese, Charles Harris
-
Patent number: 8992905Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.Type: GrantFiled: January 12, 2007Date of Patent: March 31, 2015Assignees: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara
-
Publication number: 20150086510Abstract: The present invention relates to S100 family proteins and their uses. Moreover, the present invention relates to pharmaceutical compositions comprising an S100 family protein.Type: ApplicationFiled: October 30, 2012Publication date: March 26, 2015Applicant: LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENInventors: Gerd Gauglitz, Ronald Wolf
-
Publication number: 20150086509Abstract: The present invention provides for methods and compositions for treating cancer. A subject having cancer is administered an interferon and an inhibitor of mitogen-activated protein kinase (MAPK) signaling pathway. The combination of the interferon and the inhibitor of the MAPK pathway produces a synergistic effect on the cancer compared to the effect of the interferon or the inhibitor of the MAPK pathway alone. The activity of the interferon pathway, interferon expression levels and/or interferon locus copy number can be used as biomarkers for treatment of cancer by MAPK pathway inhibitors.Type: ApplicationFiled: September 25, 2014Publication date: March 26, 2015Inventors: Oren Litvin, Neal Rosen, Dana Pe'er
-
Patent number: 8986732Abstract: This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.Type: GrantFiled: August 12, 2013Date of Patent: March 24, 2015Assignee: Helix BioPharma CorporationInventor: Praveen Kumar
-
Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
Publication number: 20150079028Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.Type: ApplicationFiled: August 5, 2013Publication date: March 19, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTDInventors: Yingjun Zhang, Jaincun Zhang, Hongming Xie, Qingyun Ren, Yumei Tan, Huichao Luo -
Publication number: 20150079025Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.Type: ApplicationFiled: June 12, 2014Publication date: March 19, 2015Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu
-
Publication number: 20150079036Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor: Chung K. Chu
-
Patent number: 8980267Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.Type: GrantFiled: March 4, 2013Date of Patent: March 17, 2015Assignee: ImmunGene IncInventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
-
Publication number: 20150071880Abstract: Methods for the treatment of lesions originating in an epithelial layer, particularly diseases of the epithelium of the skin, bladder, oral mucosa, vagina and cervix are described. Also described are uses and formulations for the treatment of lesions originating in an epithelial layer.Type: ApplicationFiled: November 18, 2014Publication date: March 12, 2015Inventor: Minas Theodore Coroneo
-
Publication number: 20150071992Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.Type: ApplicationFiled: November 25, 2014Publication date: March 12, 2015Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
-
Publication number: 20150064118Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: September 15, 2014Publication date: March 5, 2015Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Publication number: 20150064136Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.Type: ApplicationFiled: November 6, 2014Publication date: March 5, 2015Applicant: The University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Larisa Geskin, Oleg E. Akilov
-
Publication number: 20150064135Abstract: The invention relates to medicine and comprises an agent for the treatment of a viral hepatitis C, which is glutaryl histamine or a pharmaceutically acceptable salt thereof. This agent can also be administered in combination with a pegylated interferon and ribavirin. The invention further relates to a pharmaceutical composition for the treatment of a viral hepatitis C. This invention solves the problem of providing a novel agent, which is effective in the treatment of a viral hepatitis C and makes it possible to produce a sustained virologic response.Type: ApplicationFiled: March 13, 2013Publication date: March 5, 2015Inventors: Vladimir Evgenievich Nebolsin, Dmitry Yurievich Konstantinov, Larisa Leonidovna Popova, Elena Alekseevna Strebkova, Petr Grigorievich Deryabin
-
Patent number: 8968716Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: GrantFiled: September 2, 2010Date of Patent: March 3, 2015Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20150056160Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.Type: ApplicationFiled: February 24, 2014Publication date: February 26, 2015Inventors: Nicholas Bachynsky, Woodie Roy
-
Publication number: 20150056167Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: September 4, 2014Publication date: February 26, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150056166Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.Type: ApplicationFiled: March 22, 2013Publication date: February 26, 2015Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
-
Publication number: 20150050237Abstract: The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.Type: ApplicationFiled: March 13, 2013Publication date: February 19, 2015Inventors: Vasu Nair, Maurice O. Okello, Machhindra G. Gund, Byung I. Seo, Pankajkumar R. Singh, Naveen K. Mangu
-
Patent number: 8956623Abstract: The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion interferon is represented by formula (I) or formula (II), (Porcine interferon)-(Linker)n-(Porcine immunoglobulin Fc fragment) ??(I) (Porcine immunoglobulin Fc fragment)-(Linker)n-(Porcine Interferon) ??(II) wherein n is 0 or a positive integer between 1 to 10, the recombinant fusion IFN specifically binds an antibody that specifically binds porcine interferon and an antibody that specifically binds porcine immunoglobulin Fc fragment.Type: GrantFiled: July 17, 2013Date of Patent: February 17, 2015Assignee: SBC Virbac LimitedInventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20150044169Abstract: Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.Type: ApplicationFiled: September 23, 2014Publication date: February 12, 2015Inventors: Shirit Einav, Jeffrey S. Glenn, Robert McDowell, Wenjin Yang, Hadas Dvory-Sobol
-
Publication number: 20150044276Abstract: This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.Type: ApplicationFiled: October 21, 2013Publication date: February 12, 2015Applicant: Helix BioPharma CorporationInventor: Praveen Kumar
-
Publication number: 20150044292Abstract: This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.Type: ApplicationFiled: October 21, 2013Publication date: February 12, 2015Applicant: Helix BioPharma CorporationInventor: Praveen Kumar
-
Publication number: 20150044274Abstract: This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.Type: ApplicationFiled: August 12, 2013Publication date: February 12, 2015Applicant: Helix BioPharma CorporationInventor: Praveen Kumar
-
Publication number: 20150044165Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.Type: ApplicationFiled: April 29, 2014Publication date: February 12, 2015Inventors: Lieping CHEN, Scott E. STROME, Eugene D. KWON
-
Publication number: 20150044148Abstract: The invention relates to a method of treating capillary hemangiomas in a human in need thereof by topically administering an effective amount of one or more alpha-2 adrenergic receptors agonist to the site of the capillary hemangiomas on the skin of the human.Type: ApplicationFiled: October 15, 2012Publication date: February 12, 2015Inventor: Warren J. Scherer
-
Publication number: 20150044164Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: November 19, 2012Publication date: February 12, 2015Applicant: GENZYME CORPORATIONInventors: Johanne KAPLAN, John M. McPHERSON
-
Publication number: 20150044275Abstract: This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.Type: ApplicationFiled: August 12, 2013Publication date: February 12, 2015Applicant: Helix BioPharma CorporationInventor: Praveen Kumar
-
Publication number: 20150037281Abstract: The present invention relates to novel Prothymosin Alpha (ProT?) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProT?. The variants of the invention are used in methods of treating, for example, viral infections, bacterial infections, fungal infections, cancer, ischemia and myeloproliferative blood disorders. Administration of a ProT? variant to a subject in a therapeutically effective amount treats the infection or disease.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Applicant: Icahn School of Medicine at Mount SinaiInventors: Arevik Mosoian, Avelino Teixeira